All 3 NOS isoforms are expressed in the lung [62,66]. There is evidence that NO is involved in lung growth and development, in so far as eNOS knockout mice have defective lungs with a poorly developed air-blood barrier, which simulates the alveolar-capillary dysplasia . Expression and activity of eNOS are developmentally regulated, with large increases in both in late gestation .
Loss of NO is implicated in pulmonary hypertension. Administration of NOS inhibitors, such as NG-nitro-L-arginine methyl ester (L-NAME), increases pulmonary vascular resistance and augments pulmonary vasoconstrictor responses to hypoxia . Mice deficient in eNOS are more sensitive to hypoxia-induced pulmonary hypertension [19,73], whereas overexpression of eNOS in the lung is partially protective [63,13]. Patients with pulmonary hypertension have lower NO levels in their exhaled breath, a lower plasma L-citrulline/L-arginine ratio, lower urinary NO metabolites, and impaired endothelial-dependent vasorelaxation [42,50,56,26]. Furthermore, both inhaled NO and phosphodiesterase type 5 inhibitors, which act to increase NO-mediated cGMP signalling, have emerged as therapeutic options for pulmonary hypertension [23,38,89].
Reduced eNOS protein in lung tissues from patients with pulmonary hypertension has been described, which may again account for the low NO levels . However, others have found normal or even increased levels of eNOS in their patients [54,91]. Indeed, mice with hypoxia-induced pulmonary hypertension have increased eNOS protein levels, without a concomitant increase in NO bioactivity [20,48]. These data suggest that eNOS may be dysfunctional rather than deficient.
Was this article helpful?
Do You Suffer From High Blood Pressure? Do You Feel Like This Silent Killer Might Be Stalking You? Have you been diagnosed or pre-hypertension and hypertension? Then JOIN THE CROWD Nearly 1 in 3 adults in the United States suffer from High Blood Pressure and only 1 in 3 adults are actually aware that they have it.